Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 178
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 10  |  Issue : 2  |  Page : 84-90

Combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy in stage IVA ovarian carcinoma: Single institution experience from North India


1 Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
2 Department of Surgical Oncology, Mahavir Cancer Sansthan, Patna, Bihar, India

Correspondence Address:
Navin Kumar
Department of Surgical Oncology, Mahavir Cancer Sansthan, Patna, Bihar
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ccij.ccij_154_20

Rights and Permissions

Introduction: Treatment of Stage IVA ovarian carcinoma needs a combined multidisciplinary team approach. The peritoneal disease needs adequate local treatment with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Hyperthermic intrathoracic chemotherapy (HITHOC) is a reasonable treatment option for ovarian carcinoma with malignant pleural effusion or pleural deposits. The CRS with HIPEC and HITHOC needs collaborative surgical and anesthetic skills and is a more technically demanding procedure. Methods: We are sharing the experience of three advanced cases diagnosed with Stage IVA ovarian carcinoma with subdiaphragmatic deposits along with malignant pleural effusion, which were treated with CRS with combined HIPEC and HITHOC. The feasibility of combined HIPEC and HITHOC along with surgical sequelae and follow-up treatment outcomes are individually summarized. Results: All patients underwent the proposed surgery without any significant intraoperative complications. The postoperative morbidity was acceptable with no recorded mortality. One patient developed recurrent pleural disease on follow-up. Conclusions: HIPEC/HITHOC is an effective and safe therapeutic option to prevent recurrence in Stage IVA ovarian carcinoma, which has previously a dismal prognosis. In addition, the patient's general condition improved symptomatically and the respiratory distress level significantly reduced after the curative-intent treatment.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed160    
    Printed12    
    Emailed0    
    PDF Downloaded5    
    Comments [Add]    

Recommend this journal